...Kura Oncology completed its reverse-merger with shell company Zeta Acquisition Corp. III. The non-trading public company will seek to... ...New Brunswick, N.J.) to develop and commercialize tipifarnib, a farnesyl transferase inhibitor, to treat cancer. Zeta Acquisition Corp. III...
...Kura Oncology completed its reverse-merger with shell company Zeta Acquisition Corp. III. The non-trading public company will seek to... ...New Brunswick, N.J.) to develop and commercialize tipifarnib, a farnesyl transferase inhibitor, to treat cancer. Zeta Acquisition Corp. III...